SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001000694-23-000039
Filing Date
2023-05-09
Accepted
2023-05-09 07:59:02
Documents
15
Period of Report
2023-05-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K nvax-20230509.htm   iXBRL 8-K 52629
2 EX-99.1 a1q23earningspressrelease_.htm EX-99.1 74074
3 EX-99.2 cicpressrelease_final.htm EX-99.2 21790
7 image_0.jpg GRAPHIC 20101
  Complete submission text file 0001000694-23-000039.txt   333663

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT nvax-20230509.xsd EX-101.SCH 1912
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT nvax-20230509_lab.xml EX-101.LAB 23832
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT nvax-20230509_pre.xml EX-101.PRE 12518
9 EXTRACTED XBRL INSTANCE DOCUMENT nvax-20230509_htm.xml XML 10837
Mailing Address 21 FIRSTFIELD ROAD GAITHERSBURG MD 20878
Business Address 21 FIRSTFIELD ROAD GAITHERSBURG MD 20878 240-268-2000
NOVAVAX INC (Filer) CIK: 0001000694 (see all company filings)

IRS No.: 222816046 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-26770 | Film No.: 23900037
SIC: 2836 Biological Products, (No Diagnostic Substances)